Social and behavioral science in HIV vaccine trials: A gap assessment of the literature

Expert Review of Vaccines

Volumn 8, Issue 2, 2009, Pages 179-190

  Lau, Chuen Yen ^a   Stansbury, James P ^b   Gust, Deborah A ^c   Kafaar, Zuhayr ^d  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b ENCOMPASS LLC   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Clinical trial; HIV; Social science; Sociobehavioral; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; WART VIRUS VACCINE;

CLINICAL RESEARCH; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN RIGHTS; INFECTION CONTROL; INFECTION PREVENTION; INTERDISCIPLINARY RESEARCH; PATIENT PARTICIPATION; PREDICTION; PRIORITY JOURNAL; REVIEW; SOCIAL BEHAVIOR; SOCIAL PSYCHOLOGY; SOCIOLOGY; VACCINATION; WART VIRUS;

AIDS VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; SOCIAL BEHAVIOR;

EID: 60149086977     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.8.2.179     Document Type: Review

References (111)

1. Wolfe RM, Sharp LK. Anti- vaccinationists past and present. BMJ 325, 430-432 (2002).
2. Poland GA, Jacobson RM. Understanding those who do not understand: a brief review of the anti-vaccine movement. Vaccine 19, 2440-2445 (2001).
3. Gangarosa EJ, Galazka AM, Wolfe CR et al. Impact of anti-vaccine movements on pertussis control: the untold story. Lancet 351(9099), 356-361 (1998).
4. Wakefield AJ, Murch SH, Anthony A et al. Ileal lymphoid nodular hyperplasia, nonspecific colitis and regressive developmental disorder in children. Lancet 351, 637-641 (1998).
5. Gout O, Lyon-Caen O. Sclerose en plaques et vaccination contre le virus de l'hepatite B. Rev. Neurol. (Paris) 154, 205-207 (1998).
6. Classen DC, Classen JB. The timing of pediatric immunization and the risk of insulin-dependent diabetes mellitus. Infect. Dis. Clin. Pract. 6, 449-454 (1997).
7. Odent MR, Culpin EE, Kimel T. Pertussis vaccination and asthma: is there a link? JAMA 272, 591-592 (1994).
8. Hardon. Immunization: global programs, local acceptance and resistance. In: Encyclopedia of Medical Anthropology. Ember CR, Ember M (Eds). Kluwer, NY, USA 262-268 (2000).
9. Nichter M. Vaccinations in the Third World: a consideration of community demand. Soc. Sci. Med. 41(5), 617-632 (1995).
10. Gust DA, Campbell S, Kennedy A, Shui I, Barker L, Schwartz B. Parental concerns and medical-seeking behavior after immunization. Am. J. Prev. Med. 31, 32-35 (2006).
11. Offit PA, Davis RL, Gust D. Vaccine safety. In: Vaccines (5th Edition). Plotkin SA, Orenstien WA, Offit PA (Eds). Saunders Elsevier, FL, USA 1629-1650 (2008).
12. Streefland PH. Introduction of a HIV vaccine in developing countries: social and cultural dimensions. Vaccine 21(13-14), 1304-1309 (2003).
13. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev. Med. 45(2-3), 107-114 (2007).
14. Scarinci IC, Garces-Palacio IC, Partridge EE. An examination of acceptability of HPV vaccination among African American women and Latina immigrants. J. Womens Health (Larchmt) 16(8), 1224-1233 (2007).
15. Smith PG, Morrow RH. Special programme for research and training in tropical diseases. In: Field Trials of Health Interventions in Developing Countries: a Toolbox (2nd Edition). Oxford University Press, Oxford, UK (1996).
16. Whiteford L. Community health assessment. In: Training Manual in Applied Medical Anthropology. Hill CE (Ed.). American Anthropological Association, DC, USA 101-124 (1991).
17. Olin J, Kokolamami J, Lepira FB et al. Community preparedness for HIV vaccine trials in the Democratic Republic of Congo. Cult. Health Sex 8(6), 529-544 (2006).
18. Newman PA, Seiden DS, Roberts KJ, Kakinami L, Duan N. A small dose of HIV? HIV vaccine mental models and risk communication. Health Educ. Behav. DOI:10.1177/1090198107305078 (2007) (Epubahead of print).
19. Milford C, Barsdorf N, Kafaar Z. What should South African HIV vaccine trials do about social harms? AIDS Care 19(9), 1110-1117 (2007).
20. Barrington C, Moreno L, Kerrigan D. Local understanding of an HIV vaccine and its relationship with HIV-related stigma in the Dominican Republic. AIDS Care 19(7), 871-877 (2007).
21. Brooks RA, Newman PA, Duan N, Ortiz DJ. HIV vaccine trial preparedness among Spanish-speaking Latinos in the US. AIDS Care 19(1), 52-58 (2007).
22. Newman PA, Duan N, Roberts KJ et al. HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment. J. Acquir. Immune Defic. Syndr. 41(2), 210-217 (2006).
23. Cho H, Witte K. Managing fear in public health campaigns: a theory-based formative evaluation process. Health Promot. Pract. 6(4), 482-490 (2005).
24. Coreil J, Losikoff P, Pincu R et al. Cultural feasibility studies in preparation for clinical trials to reduce maternal-infant HIV transmission in Haiti. AIDS Educ. Prev. 10(1), 46-62 (1998).
25. Corneli AL, Piwoz EG, Bentley ME et al. Involving communities in the design of clinical trial protocols: the BAN Study in Lilongwe, Malawi. Contemp. Clin. Trials 28(1), 59-67 (2007).
26. Wagner G, Ryan G, Taylor S. Formative evaluation of antiretroviral therapy scale-up efficiency in sub-Saharan Africa. AIDS Patient Care STDS 21(11), 871-888 (2007).
27. Fourney AM, Williams ML. Formative evaluation of an intervention to increase compliance to HIV therapies: the ALP project. Health Promot. Pract. 4(2), 165-170 (2003).
28. Mayer JP, Housemann R, Piepenbrok B. Evaluation of a campaign to improve immunization in a rural headstart program. J. Community Health 24(1), 13-27 (1999).
29. NIMH Collaborative HIV/STD Prevention Trial Group. Formative study conducted in five countries to adapt the community popular opinion leader intervention. AIDS 21(Suppl. 2), S91-S98 (2007).
30. NIMH Collaborative HIV/STD Prevention Trial Group. Design and integration of ethnography within an international behavior change HIV/sexually transmitted disease prevention trial. AIDS 21(Suppl. 2), S37-S48 (2007).
31. Epstein H. The Invisible Cure: Africa, the West, and the Fight Against AIDS. Farrar Straus and Giroux, NY, USA (2007).
32. Newman PA, Duan N, Kakinami L, Roberts K. What can HIV vaccine trials teach us about future HIV vaccine dissemination? Vaccine 26(20), 2528-2536 (2008).
33. Bishai D, Pariyo G, Ainsworth M, Hill K. Determinants of personal demand for an AIDS vaccine in Uganda: contingent valuation survey. Bull. World Health Organ. 82(9), 652-660 (2004).
34. Mills E, Cooper C, Guyatt G et al. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS 18(17), 2235-2242 (2004).
35. Lesch A, Kafaar Z, Kagee A, Swartz L. Community members' perceptions of enablers or inhibitors to participation in HIV vaccine trials. S. Afr. J. Psychol. 36(4), 734-761 (2006).
36. Swartz L, Kagee A. Community participation in AIDS vaccine trials: empowerment or science? Soc. Sci. Med. 63(5), 1143-1146 (2006).
37. Kafaar Z, Swartz L, Kagee A, Lesch A, Jaspan H. Adolescent participation in HIV vaccine trials: cognitive developmental considerations. S. Afr. J. Psychol. 37(3), 576-594 (2007).
38. McClure CA, Gray G, Rybczyk GK, Wright PF. Challenges to conducting HIV preventive vaccine trials with adolescents. J. Acquir. Immune Defic. Syndr. 36 (2), 726-733 (2004).
39. Swartz L, Kagee A, Kafaar Z et al. Social and behavioral aspects of child and adolescent participation in HIV vaccine trials. J. Int. Assoc. Physicians AIDS Care (Chic. Ill) 4(4), 89-92 (2005).
40. Buchbinder SP, Metch B, Holte SE et al. Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J. Acquir. Immune Defic. Syndr. 36(1), 604-612 (2004).
41. Koblin BA, Heagerty P, Sheon A et al. Readiness of high-risk populations in the HIV network for prevention trials to participate in HIV vaccine efficacy trials in the United States. AIDS 12(7), 785-793 (1998).
42. Sahay S, Mehendale S, Sane S et al. Correlates of HIV vaccine trial participation: an Indian perspective. Vaccine 23(11), 1351-1358 (2005).
43. Strauss RP, Sengupta S. Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three U.S. communities. J. Acquir. Immune Defic. Syndr. 26(1), 63 (2001).
44. Allen MA, Liang TS, La Salvia T et al. Assessing the attitudes, knowledge, and awareness of HIV vaccine research among adults in the United States. J. Acquir. Immune Defic. Syndr. 40(5), 617-624 (2005).
45. Yin L, Zhang Y, Qian HZ et al. Willingness of Chinese injection drug users to participate in HIV vaccine trials. Vaccine 26(6), 762-768 (2008).
46. Jenkins RA, Torugsa K, Markowitz LE et al. Willingness to participate in HIV-1 vaccine trials among young Thai men. Sex. Transm. Infect. 76(5), 386-392 (2000).
47. MacQueen KM, Vanichseni S, Kitayaporn D et al. Willingness of injection drug users to participate in an HIV vaccine efficacy trial in Bangkok, Thailand. J. Acquir. Immune Defic. Syndr. 21(3), 243-251 (1999).
48. Jaspan HB, Berwick JR, Myer L et al. Adolescent HIV prevalence, sexual risk, and willingness to participate in HIV vaccine trials. J. Adolesc. Health 39(5), 642-648 (2006).
49. Smit J, Middelkoop K, Myer L et al. Willingness to participate in HIV vaccine research in a peri-urban South African community. Int. J. STD AIDS 17(3), 176-179 (2006).
50. Perisse AR, Schechter M, Moreira RI et al. Willingness to participate in HIV vaccine trials among men who have sex with men in Rio de Janeiro, Brazil. Projeto Praca Onze Study Group. J. Acquir. Immune Defic. Syndr. 25(5), 459-463 (2000).
51. Thapinta D, Jenkins RA, Morgan PA et al. Recruiting volunteers for a multisite Phase I/II HIV preventive vaccine trial in Thailand. J. Acquir. Immune Defic. Syndr. 30(5), 503-513 (2002).
52. Smit J, Middelkoop K, Myer L et al. Socio-behaviour challenges to Phase III HIV vaccine trials in Sub-Saharan Africa. Afr. Health Sci. 5(3), 198-206 (2005).
53. Halpern SD, Metzger DS, Berlin JA, Ubel PA. Who will enroll? Predicting participation in a Phase II AIDS vaccine trial. J. Acquir. Immune Defic. Syndr. 27(3), 281-288 (2001).
54. Seage GR 3rd Holte SE, Metzger D et al. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am. J. Epidemiol. 153(7), 619-627 (2001).
55. Brown SJ, Harro C, Mayer KH et al.; the VAX004 Study Team. VaxGen AIDSVAX B/B vaccine trial: recruitment, demographics, and changes in risk behaviors - lessons for future trials. Presented at: National HIV Prevention Conference. Atlanta, GA, USA, 27 July 2003 (Abstract T3-D0502).
56. de Bruyn G, Hudgens MG, Sullivan PS, Duerr AC. Participant retention in clinical trials of candidate HIV vaccines. J. Acquir. Immune Defic. Syndr. 39(4), 499-501 (2005).
57. Arreola S. Enrolling important target populations into HIV vaccine trials. Presented at: HIV Vaccine Trials Network Conference. DC, USA, 1-4 May 2007.
58. Giocos G, Kagee A, Swartz L. Predicting hypothetical willingness to participate (WTP) in a future Phase III HIV vaccine trial among high-risk adolescents. AIDS Behav. 12(6), 842-851 (2008).
59. Ajzen I. Attitudes, Personality and Behaviour. Dorsey, IL, USA (1988).
60. Ajzen I, Fishbein M. Understanding Attitudes and Predicting Social Behaviour. Prentice- Hall, Englewood-Cliffs, NJ, USA (1980).
61. Kafaar Z, Kagee A, Lesch A, Swartz L. Is participation in HIV vaccine trials a health promoting behaviour? AIDS Care 19(10), 1307-1309 (2007).
62. Francis DP, Heyward WL, Popovic V et al. Candidate HIV/AIDS vaccines: lessons learned from the World's first Phase III efficacy trials. AIDS 17(2), 147-156 (2003).
63. Mugerwa RD, Kaleebu P, Mugyenyi P et al. First trial of the HIV-1 vaccine in Africa: Ugandan experience. BMJ 324(7331), 226-229 (2002).
64. Mugyenyi PN. HIV vaccines: the Uganda experience. Vaccine 20(15), 1905-1908 (2002).
65. Rerks-Ngarm S, Brown AE, Khamboonruang C, Thongcharoen P, Kunasol P. HIV/AIDS preventive vaccine 'prime-boost' Phase III trial: foundations and initial lessons learned from Thailand. AIDS 20(11), 1471-1479 (2006).
66. Pitisuttithum P. HIV vaccine research in Thailand: lessons learned. Expert Rev. Vaccines 7(3), 311-317 (2008).
67. Molyneux CS, Peshu N, Marsh K. Understanding of informed consent in a low- income setting: three case studies from the Kenyan Coast. Soc. Sci. Med. 59(12), 2547-2559 (2004).
68. Newman PA. Towards a science of community engagement. Lancet 367(9507), 302 (2006).
69. DeLay P, Manda V. Politics of monitoring and evaluation: lessons from the AIDS epidemic. New Direc. Eval. (103), 13-48 (2004).
70. Fast PE, Excler JL, Warren M, Ketter N. Clinical site development and preparation for AIDS vaccine efficacy trials in developing countries. In: AIDS Vaccine Development: Challenges and Opportunities. Koff WC, Kahn P, Gust ID (Eds). Caister Academic Press, Norfolk, UK 87-98 (2007).
71. Erhabor O, Ejele OA, Nwauche CA. Epidemiology and management of occupational exposure to blood borne viral infections in a resource poor setting: the case for availability of post exposure prophylaxis. Niger. J. Clin. Pract. 10(2), 100-104 (2007).
72. Weiss R, Hardy LM. HIV infection and health policy. J. Consult. Clin. Psychol. 58(1), 70-76 (1990).
73. Weiss R, Thier SO. The Institute of Medicine, National Academy of Sciences: formulating AIDS policy. Public Health Rep. 103(3), 289-292 (1988).
74. Mann J. Worldwide strategies for HIV control: WHO's special programme on AIDS. Law Med. Health Care 14(5-6), 290-297 (1986).
75. Social aspects of HIV/AIDS and health research programme, human sciences research council. In: An Audit of HIV/AIDS Policies in Botswana, Lesotho, Mozambique, South Africa, Swaziland and Zimbabwe. Zungu-Dirwayi N, Shisana O, Udjo E, Mosala T, Seager J (Eds). HSRC Publishers, Cape Town, South Africa (2004).
76. Yusuf NK. Bio-ethical and legal issues in relation to HIV/AIDS: the Uganda experience. Med. Law 17(4), 619-624 (1998).
77. Strode A, Slack C, Mushariwa M. HIV vaccine research-South Africa's ethical-legal framework and its ability to promote the welfare of trial participants. S. Afr. Med. J. 95(8), 598-601 (2005).
78. Slack C, Stobie M, Milford C et al. Provision of HIV treatment in HIV preventive vaccine trials: a developing country perspective. Soc. Sci. Med. 60 (6), 1197-1208 (2005).
79. Slack C, Strode A, Grant C, Milford C. Implications of the ethical-legal framework for adolescent HIV vaccine trials-report of a consultative forum. S. Afr. Med. J. 95(9), 682-684 (2005).
80. Strode A, Grant C, Slack C, Mushariwa M. How well does South Africa's National Health Act regulate research involving children? S. Afr. Med. J. 95(4), 265-268 (2005).
81. Berkley SF, Koff WC. Scientific and policy challenges to development of an AIDS vaccine. Lancet 370(9581), 94-101 (2007).
82. Allen M, Israel H, Rybczyk K et al. Trial-related discrimination in HIV vaccine clinical trials. AIDS Res. Hum. Retroviruses 17(8), 667-674 (2001).
83. Cassell MM, Halperin DT, Shelton JD, Stanton D. Risk compensation: the Achilles' heel of innovations in HIV prevention? BMJ 332(7541), 605-607 (2006).
84. Allen M, Lau CY. Social impact of preventive HIV vaccine clinical trial participation: a model of prevention, assessment and intervention. Soc. Sci. Med. 66(4), 945-951 (2008).
85. Fuchs J, Durham M, McLellan-Lemal E et al. Negative social impacts among volunteers in an HIV vaccine efficacy trial. J. Acquir. Immune Defic. Syndr. 46(3), 362-368 (2007).
86. Branson BM, Handsfield HH, Lampe MA et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm. Rep. 55(RR-14), 1-17 (2006).
87. Khurana S, Needham J, Park S et al. Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes. J. Acquir. Immune Defic. Syndr. 43(3), 304-312 (2006).
88. Chesney MA, Lurie P, Coates TJ. Strategies for addressing the social and behavioral challenges of prophylactic HIV vaccine trials. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 9(1), 30-35 (1995).
89. Chesney MA, Chambers DB, Kahn JO. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 16(4), 266-271 (1997).
90. Eaton LA, Kalichman S. Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr. HIV/AIDS Rep. 4(4), 165-172 (2007).
91. Guest G, Shattuck D, Johnson L et al. Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex. Transm. Dis. 35(12), 1002-1008 (2008).
92. Mattson CL, Campbell RT, Bailey RC et al. Risk compensation is not associated with male circumcision in Kisumu, Kenya: a multi-faceted assessment of men enrolled in a randomized controlled trial. PLoS ONE 3(6), E2443 (2008).
93. Bartholow BN, Buchbinder S, Celum C et al.; VISION/VAX004 Study Team. HIV sexual risk behavior over 36 months of follow-up in the world's first HIV vaccine efficacy trial. J. Acquir. Immune Defic. Syndr. 39(1), 90-101 (2005).
94. Dhalla S, Nelson KE, Singer J, Poole G. HIV vaccine preparedness studies in the non-organization for economic co-operation and development (non-OECD) countries. AIDS Care 10, 1-15 (2008).
95. Carneiro M, de Figueiredo Antunes CM, Greco M et al. Design, implementation, and evaluation at entry of a prospective cohort study of homosexual and bisexual HIV-1-negative men in Belo Horizonte, Brazil: Project Horizonte. J. Acquir. Immune Defic. Syndr. 25(2), 182-187 (2000).
96. Kegeles SM, Johnson MO, Strauss RP et al. How should HIV vaccine efficacy trials be conducted? Diverse U.S. communities speak out. AIDS Educ. Prev. 18(6), 560-572 (2006).
97. Dittmann S. Vaccine safety: risk communication - a global perspective. Vaccine 19(17-19), 2446-2456 (2001).
98. Stover J, Bollinger L. The impact of an AIDS vaccine in developing countries: a new model and preliminary results. International AIDS Vaccine Research Initiative, Policy Research Working Paper #8. IAVI, NY, USA (2006).
99. Walensky RP, Paltiel AD, Goldie SJ et al. A therapeutic HIV vaccine: how good is good enough? Vaccine 22(29-30), 4044-4053 (2004).
100. Amirfar S, Hollenberg JP, Abdool Karim SS. Modeling the impact of a partially effective HIV vaccine on HIV infection and death among women and infants in South Africa. J. Acquir. Immune Defic. Syndr. 43(2), 219-225 (2006).
101. Boily MC, Abu-Raddad L, Desai K et al. Measuring the public-health impact of candidate HIV vaccines as part of the licensing process. Lancet Infect. Dis. 8(3), 200-207 (2008).
102. Liau A, Zimet GD, Fortenberry JD. Attitudes about human immunodeficiency virus immunization: the influence of health beliefs and vaccine characteristics. Sex. Transm. Dis. 25(2), 76-81 (1998).
103. Ware J. SF-36 Health Survey Update. Spine 25(24), 3130-3139 (2000).
104. Shahriar J, Delate T, Hays RD, Coons SJ. Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease. Health Qual. Life Outcomes 1, 25 (2003).
105. Liu C, Ostrow D, Detels R et al. Impacts of HIV infection and HAART use on quality of life. Qual. Life Res. 15(6), 941-949 (2006).
106. Meng YJ, Li NX, Chen JH, Song YC, Qian ZS. Using the SF-36 to assess the quality of life of people living with HIV in Sichuan. Sichuan Da Xue Xue Bao Yi Xue Ban 38(3), 471-474 (2007).
107. Protopopescu C, Marcellin F, Spire B et al. Health-related quality of life in HIV-1-infected patients on HAART: a five-year longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8). Qual. Life Res. 16(4), 577-591 (2007).
108. Holmes WC, Shea JA. Performance of a new, HIV/AIDS-targeted quality of life (HAT-QoL) instrument in asymptomatic seropositive individuals. Qual. Life Res. 6(6), 561-571 (1997).
109. Holmes WC, Shea JA. Two approaches to measuring quality of life in the HIV/AIDS population: HAT-QoL and MOS-HIV. Qual. Life Res. 8(6), 515-527 (1999).
110. Phaladze NA, Human S, Dlamini SB et al. Quality of life and the concept of "living well" with HIV/AIDS in sub-Saharan Africa. J. Nurs. Scholarsh. 37(2), 120-126 (2005).
111. Buchbinder S, Mehotra D, Duerr A et al. The STEP study: the first test-of-concept efficacy trial of a cell-mediated immunity HIV vaccine. Lancet 372(9653), 1881-1893 (2008).